French biotech Abivax loses a third after safety signals

Abivax reported Phase III trial results this morning for its flagship drug obefazimod for treating ulcerative colitis. STAT News reports that the company presented positive efficacy data – the drug showed therapeutic effectiveness. Yet in parallel, significant safety issues emerged: investing.com documents that malignancies occurred in patients who received the higher dose.

Stock market reaction and M&A opportunities fade

The market reacted promptly. The stock fell 32 to 33 percent, as CNBC reports. With it disappeared the so-called M&A premium – Abivax had long been considered a potential takeover target for larger pharmaceutical companies. Seeking Alpha analyzes that these acquisition prospects have been significantly diminished by the safety signal.

Obefazimod was Abivax' flagship hope. The company had positioned the substance as a breakthrough in treating inflammatory bowel diseases. The Phase III data showed that the drug works – yet the side effects at higher doses call the development into question. Regulators will now have to examine whether therapeutic benefit justifies the safety risks.

Massive consequences for the future

For Abivax, this represents a massive setback. The company must now clarify with authorities how it can proceed with the program – possibly with lower doses or additional safety measures. Investors who had hoped for rapid approval and acquisition are selling their positions.